Lori Bacon, MD | |
3333 Springhill Dr, North Little Rock, AR 72117-2922 | |
(501) 202-6800 | |
Not Available |
Full Name | Lori Bacon |
---|---|
Gender | Female |
Speciality | Emergency Medicine |
Experience | 27 Years |
Location | 3333 Springhill Dr, North Little Rock, Arkansas |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1073612883 | NPI | - | NPPES |
140205001 | Medicaid | AR |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207P00000X | Emergency Medicine | E2154 (Arkansas) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Baptist Health Medical Center North Little Rock | North little rock, AR | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Greenbrier Emergency Services, Inc. | 2668377359 | 36 |
News Archive
The list of cosmetic soft tissue fillers on the market and in the pipeline worldwide is growing rapidly. Many have been introduced with great fanfare; relatively few stand the test of regulatory or peer review - as well as the test of time.
Myths abound about the short-term and long-term consequences of use of MDMA, often called Ecstasy. MDMA is not new to the scientific community.
Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
› Verified 4 days ago
Entity Name | Arkansas Health Group |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1326133943 PECOS PAC ID: 7911802079 Enrollment ID: O20051011001164 |
News Archive
The list of cosmetic soft tissue fillers on the market and in the pipeline worldwide is growing rapidly. Many have been introduced with great fanfare; relatively few stand the test of regulatory or peer review - as well as the test of time.
Myths abound about the short-term and long-term consequences of use of MDMA, often called Ecstasy. MDMA is not new to the scientific community.
Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
› Verified 4 days ago
Entity Name | Greenbrier Emergency Services, Inc. |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1568401461 PECOS PAC ID: 2668377359 Enrollment ID: O20191011002500 |
News Archive
The list of cosmetic soft tissue fillers on the market and in the pipeline worldwide is growing rapidly. Many have been introduced with great fanfare; relatively few stand the test of regulatory or peer review - as well as the test of time.
Myths abound about the short-term and long-term consequences of use of MDMA, often called Ecstasy. MDMA is not new to the scientific community.
Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Lori Bacon, MD 11001 Executive Center Dr, Ste. 200, Little Rock, AR 72211-4316 Ph: (501) 812-7589 | Lori Bacon, MD 3333 Springhill Dr, North Little Rock, AR 72117-2922 Ph: (501) 202-6800 |
News Archive
The list of cosmetic soft tissue fillers on the market and in the pipeline worldwide is growing rapidly. Many have been introduced with great fanfare; relatively few stand the test of regulatory or peer review - as well as the test of time.
Myths abound about the short-term and long-term consequences of use of MDMA, often called Ecstasy. MDMA is not new to the scientific community.
Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.
Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.
› Verified 4 days ago
Dr. James E Darr Iii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3333 Springhill Dr, North Little Rock, AR 72117 Phone: 501-202-6800 | |
Nastasya Jabaly, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3333 Springhill Dr, North Little Rock, AR 72117 Phone: 501-202-3802 | |
Leslie Howard Sessions, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 5201 Northshore Dr, North Little Rock, AR 72118 Phone: 501-313-4271 Fax: 501-313-4268 | |
Tyler Welch, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 3201 Springhill Dr Ste 300, North Little Rock, AR 72117 Phone: 501-753-4132 | |
Dr. Samuel W. Norwood Ii, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2215 Wildwood Ave, North Little Rock, AR 72120 Phone: 501-552-7100 | |
James Rice, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 3333 Springhill Dr, North Little Rock, AR 72117 Phone: 501-202-6800 |